AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35134489
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate 0.2% mouthwash (prescribed twice daily)
Trial: 35026987
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (various pre/post-partum dose combinations)
Trial: 34079227
Drug: Dezocine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine 0.8 mg/kg (Group D)
Trial: 34079227
Drug: Sufentanil 2
RxNorm normalized name: SUFentanil 250 MCG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2 µg/kg (Group S)
Trial: 32909365
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg of Ellagic acid per day
Trial: 32641142
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (ESWT) in addition to conventional therapy
Trial: 32641142
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment including medication therapy and invasive interventional therapy
Trial: 32307431
Drug: Mexidol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol (500 mg IV once daily for 14 days, then Mexidol Forte 250 (250 mg, 3 times a day for 60 days)
Trial: 32307431
Drug: Standard basic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard basic therapy (comparison group)
Trial: 32056985
Drug: High-intensity negative
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity negative ion patch treatment
Trial: 32483770
Drug: Desmopressin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (0.3 μg/kg)
Trial: 32450915
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus hydroxychloroquine monotherapy
Trial: 34229074
Drug: Placebo intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion
Trial: 35779110
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (BT) + pelvic floor muscle training (PFMT) + anticholinergic + beta3‐agonist
Trial: 35779110
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (BT) + anticholinergic + beta3‐agonist
Trial: 32166544
Drug: Systemic sedoanalgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic sedoanalgesia (intravenous remifentanil/fentanyl ± intravenous midazolam ± intravenous acetaminophen/nonsteroidal anti‐inflammatory drugs) + subcutaneous anesthesia (lidocaine)
Trial: 32166544
Drug: Mild systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild systemic sedoanalgesia (oral solution morphine sulfate + intravenous midazolam + intravenous acetaminophen) + both subcutaneous and subcapsular anesthesia (mepivacaine + bupivacaine)
Trial: 33802381
Drug: Resveratrol (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (lower dose)
Trial: 33802381
Drug: Resveratrol (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (higher dose)
Trial: 33802381
Drug: Luteolin (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteolin (lower dose)
Trial: 33802381
Drug: Luteolin (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteolin (higher dose)
Trial: 33802381
Drug: Fisetin (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fisetin (lower dose)
Trial: 33802381
Drug: Fisetin (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fisetin (higher dose)
Trial: 32470438
Drug: Deferiprone (75-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone (75-100 mg/kg per day)
Trial: 32470438
Drug: Deferasirox (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (20-40 mg/kg per day)
Trial: 34313812
Drug: Tofacitinib (TOF)
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib (TOF) 5 mg orally twice a day
Trial: 33055139
Drug: Control (user-determined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (user-determined insulin dosing)
Trial: 34077237
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with modified oxaliplatin, leucovorin, and fluorouracil (FOLFOX)
Trial: 34077237
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with carboplatin‐paclitaxel (CP)
Trial: 33185339
Drug: Targeted antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted antibiotic therapy
Trial: 33185339
Drug: Local peloid
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local peloid therapy
Trial: 34611700
Drug: Video-assisted anal
RxNorm normalized name: Mephitis mephitis anal gland fluid preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-assisted anal fistula treatment (VAAFT)
Trial: 32546278
Drug: Celecoxib (COX2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (COX2 selective inhibitor)
Trial: 33578615
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS combined with constraint-induced movement therapy (CIMT)
Trial: 34863994
Drug: Quercetin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (1000 mg daily) + antiviral drugs (remdesivir or favipiravir)
Trial: 34863994
Drug: Antiviral drugs
RxNorm normalized name: antiviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drugs (remdesivir or favipiravir)
Trial: 35909493
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) combined with conventional rehabilitation therapy (CRT)
Trial: 35909493
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation therapy (CRT) alone
Trial: 35320282
Drug: Cell block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell block preparation
Trial: 35320282
Drug: Combined conventional
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined conventional cytology and cell block preparation
Trial: 34599663
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment (specifics not provided)
Trial: 35840916
Drug: MG plus
RxNorm normalized name: MG Plus Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG plus A-MRI
Trial: 35840916
Drug: MG alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG alone
Trial: 35384254
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent (DTS)
Trial: 32409485
Drug: Cenobamate 200
RxNorm normalized name: cenobamate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate 200 mg/d
Trial: 34329984
Drug: HS+BT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS+BT group (1,000 mg/kg betaine)
Trial: 35373026
Drug: Ziltivekimab 15
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab 15 mg subcutaneous injection
Trial: 35373026
Drug: Ziltivekimab 50
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab 50 mg subcutaneous injection
Trial: 35373026
Drug: Ziltivekimab 5
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab 5 mg subcutaneous injection
Trial: 32532230
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel plus ramucirumab (wPTX + RAM)
Trial: 32532230
Drug: Weekly nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly nab-paclitaxel plus ramucirumab (w-nab-PTX + RAM)
Trial: 35757181
Drug: Antioxidant supplement
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplement (NingXia RedⓇ), 60 ml daily for 60 days
Trial: 32727335
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids and nano-curcumin combination
Trial: 38429253
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg once daily)
Trial: 33169203
Drug: Oxycodone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone + Alcohol
Trial: 35667085
Drug: 1,300mg TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,300mg TXA orally or 1,000mg TXA intravenously thrice daily for maximum 30 days
Trial: 34226418
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg atropine and 2 mg neostigmine
Trial: 32816002
Drug: Anti-VEGF treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-VEGF treatment, with varying fluctuations in retinal thickness (measured by FCPT SD).
Trial: 35148329
Drug: COTiD-UK (Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COTiD-UK (Community Occupational Therapy in Dementia-UK version)
Trial: 35288021
Drug: HRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT plus letrozole (2.5 mg oral letrozole twice daily for 5 days, with continuation of daily oestradiol)
Trial: 35288021
Drug: HRT only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT only (daily intramuscular progesterone plus daily oestradiol)
Trial: 32460396
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) with a dose of 12 J/cm2 during 10 sessions
Trial: 32121236
Drug: Omega-3 long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 long chain polyunsaturated fatty acids (OM, 722 mg/day docosahexaenoic acid)
Trial: 34389930
Drug: Patch pump
RxNorm normalized name: subcut bolus insulin patch pump,200 unit,disposabl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch pump
Trial: 33706870
Drug: Standard systolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systolic blood pressure treatment (<140 mm Hg)
Trial: 34289428
Drug: Chai Hu
RxNorm normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chai Hu oral liquid high dosage
Trial: 34289428
Drug: Chai Hu
RxNorm normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chai Hu oral liquid middle dosage
Trial: 34289428
Drug: Chai Hu
RxNorm normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chai Hu oral liquid low dosage
Trial: 32398326
Drug: Cardiopulmonary irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardiopulmonary irradiation (specific doses not detailed)
Trial: 35647186
Drug: Nicorandil tablets
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil tablets
Trial: 34044869
Drug: Sequential implementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential implementation strategy (first centered on nurses, then involving physicians)
Trial: 34044869
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of lifestyle change
Trial: 35297768
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health intervention delivered via an existing service communication app for 10 weeks, including weekly push notifications and resources.
Trial: 35466050
Drug: Diltiazem (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (up to 360 mg/d)
Trial: 35063267
Drug: telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 40 mg/day + amlodipine 5 mg/day
Trial: 35063267
Drug: telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 40 mg/day + cilnidipine 10 mg/day
Trial: 35394159
Drug: Dexmedetomidine (alpha2-agonist)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (alpha2-agonist)
Trial: 35394159
Drug: Yohimbine (alpha2-antagonist)
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (alpha2-antagonist)
Trial: 33804123
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (Control)
Trial: 33118429
Drug: Spirulina (5.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina (5.7 g/d)
Trial: 33153313
Drug: Remote symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote symptom monitoring intervention, delivered during daily automated coaching
Trial: 35025558
Drug: COPE (Concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPE (Concurrent Treatment of PTSD and SUD Using Prolonged Exposure)
Trial: 35025558
Drug: Relapse Prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse Prevention (RP) therapy for SUD
Trial: 37488811
Drug: Apremilast (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast (30 mg twice daily)
Trial: 33712987
Drug: Methotrexate (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (0.4 mg/kg/week orally)
Trial: 34802925
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of dexmedetomidine (0.1 mg kg–1) with midazolam (2 mg kg–1)
Trial: 34802925
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of dexmedetomidine (0.1 mg kg–1) with midazolam (2 mg kg–1)
Trial: 34802925
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (IN and IM)
Trial: 33260183
Drug: Oxycodone combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone combined with propofol (group OP)
Trial: 34264835
Drug: Antidepressant Treatment
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant Treatment (AT) group
Trial: 32331886
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (FM and BM)
Trial: 35867199
Drug: Imeglimin (250–8000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imeglimin (250–8000 mg single dose; 250–2000 mg twice daily multiple doses)
Trial: 36193713
Drug: Liraglutide 3
RxNorm normalized name: liraglutide 3.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3 mg administered subcutaneously daily
Trial: 36193713
Drug: Liraglutide 3
RxNorm normalized name: liraglutide 3.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3 mg
Trial: 32302682
Drug: Postoperative tangential
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative tangential whole breast radiation therapy (RT)
Trial: 32302682
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (Control group)
Trial: 32784412
Drug: High-gamma-polyglutamic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-gamma-polyglutamic acid (HPGA) natto (439.6 mg of γ-PGA)
Trial: 32784412
Drug: Low-gamma-polyglutamic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-gamma-polyglutamic acid (LPGA) natto (57.6 mg of γ-PGA)
Trial: 32293798
Drug: Temsirolimus 115
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 115 mg weekly and perifosine 100 mg daily (following 600 mg load)
Trial: 32293798
Drug: Temsirolimus 50
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 50 mg (dose level 3)
Trial: 32293798
Drug: Temsirolimus 170
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 170 mg (dose level 7)
Trial: 32293798
Drug: Temsirolimus 170
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 170 mg (dose level 6)
Trial: 32293798
Drug: Temsirolimus (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (various doses)
Trial: 36121655
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (control)
Trial: 32268867
Drug: Insulin U‐500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin U‐500
Trial: 32147078
Drug: 600 IU
RxNorm normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 IU alpha-tocopherol soft gels (200 IU three times daily)
Trial: 32147078
Drug: Placebo soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo soft gels
Trial: 33768237
Drug: Secnidazole 2
RxNorm normalized name: secnidazole 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secnidazole 2 g single oral dose
Trial: 35493455
Drug: mepolizumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepolizumab 300 mg subcutaneously every 4 weeks for 32 weeks
Trial: 36113708
Drug: Craniosacral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniosacral therapy (CST) sessions (1-3 sessions until symptoms resolved)
Trial: 33831317
Drug: CHO-replace (treadmill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-replace (treadmill exercise followed by a carbohydrate replacement drink of 200 or 150 g maltodextrin)
Trial: 36122810
Drug: Ingesting 75-g
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingesting 75-g glucose
Trial: 35556054
Drug: BH4 (Sapropterin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BH4 (Sapropterin, 10 mg/kg)
Trial: 32342496
Drug: Nabiximols (oromucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabiximols (oromucosal cannabinoid medicine), 12 sprays/day max based on clinical response/tolerability for 12 weeks
Trial: 35606184
Drug: Perioperative nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative nutritional supplements
Trial: 36286574
Drug: Customized Photobiomodulation
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized Photobiomodulation (PBMT) applied using 850 nm with continuous wave, total of 526-1402 J each session, twice a week for 5 weeks
Trial: 33237990
Drug: Mindfulness-exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-exercise group (8-week mindfulness intervention + 18 weeks exercise therapy, 3 sessions/week)
Trial: 33237990
Drug: Exercise-only group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise-only group (18 weeks exercise therapy, 3 sessions/week)
Trial: 33774458
Drug: 0.15−0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15−0.2 mg/kg nalbuphine
Trial: 33774458
Drug: 0.75–1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75–1.0 mg/kg tramadol
Trial: 34241688
Drug: Combination method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination method cohort using contrast-enhanced ultrasonography (CEUS) and blue dye (BD) together
Trial: 34241688
Drug: Combination method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination method cohort
Trial: 34444711
Drug: Berberine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine (500 mg orally, twice a day)
Trial: 32316918
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of audio and visual distraction
Trial: 33827105
Drug: Univariate analyses
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Univariate analyses of 9 depression treatment metrics
Trial: 34182951
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (small tidal volume 8 mL/kg + PEEP 5 cmH2O)
Trial: 34182951
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (small tidal volume 8 mL/kg + PEEP 5 cmH2O + recruitment maneuvers)
Trial: 32323940
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without cortexin (Control)
Trial: 34700679
Drug: Curative intent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Curative intent radiation therapy